1. Introduction {#sec1-ijms-21-05387}
===============

Non-genotoxic carcinogens (NGTXCs) induce tumors through a variety of non-DNA-damaging mechanisms during carcinogenesis. Twelve percent (45/371) of IARC Group 1, 2A, and 2B carcinogens appear to be non-genotoxic \[[@B1-ijms-21-05387]\]. NGTXCs are traditionally identified only in vivo in two-year rodent bioassays because there are currently no accurate or well validated in vitro assays. In vitro cell transformation assays (CTAs), which mimic different stages of the in vivo neoplastic process, have been reported to be useful for detecting possible NGTXCs \[[@B2-ijms-21-05387],[@B3-ijms-21-05387]\]. In particular, CTAs using Bhas 42 cells are capable of detecting promotor activities without initiator treatment, and thus are superior to those of the BALB/c 3T3 CTA and other CTAs (Validation Study Report \[[@B4-ijms-21-05387],[@B5-ijms-21-05387]\]). In recent years, the Bhas 42 CTA has undergone several comprehensive international validation studies \[[@B4-ijms-21-05387],[@B6-ijms-21-05387],[@B7-ijms-21-05387]\] and is now the subject of an OECD guidance document \[[@B8-ijms-21-05387]\].

The importance of a mechanism-based approach in the risk assessment of NGTXCs has risen. However, current CTAs do not provide information on key molecular events supporting the carcinogenesis process of NGTXCs. In fact, NGTXCs have a number of relatively diverse modes of action, including epigenetic alterations, tumor promotion, endocrine modulation, immune suppression, and inflammatory responses \[[@B1-ijms-21-05387],[@B9-ijms-21-05387],[@B10-ijms-21-05387],[@B11-ijms-21-05387]\]. Owing to this diversity, it is impossible to detect all NGTXCs in one test system \[[@B1-ijms-21-05387]\]. Presumably, the performance of a test battery to cover all the modes of action of NGTXCs is time-consuming and complex. Many studies have highlighted that the mode of action of NGTXCs may involve epigenetic alteration, including altered DNA methylation, histone modification, non-coding RNA, and chromatin remodeling \[[@B12-ijms-21-05387],[@B13-ijms-21-05387]\]. With this, it has become clear that epigenetic dysregulation is a characteristic of virtually all human cancers \[[@B14-ijms-21-05387]\]. Of these alterations, DNA methylation is demonstrably heritable \[[@B15-ijms-21-05387]\], rendering DNA methylation the standard epigenetic marker \[[@B16-ijms-21-05387]\]. Furthermore, changes in gene expression patterns based on altered DNA methylation have been linked to various cancers \[[@B17-ijms-21-05387]\]. Using a massively parallel sequencing-based approach, it is relatively easy to generate comprehensive genome-wide methylation profiles. Reduced-representation bisulfite sequencing (RRBS) is an economical, accurate, and efficient method for analyzing the DNA methylation of a single base \[[@B18-ijms-21-05387],[@B19-ijms-21-05387]\]. This method enriches the promoter and CpG island regions by methylation-insensitive restriction endonuclease digestion, providing a locus-specific methylation analysis for roughly 6--8% of the CpG loci in the human genome \[[@B20-ijms-21-05387]\]. Moreover, several laboratories have combined in vitro CTAs with several endpoint applications, such as protein analysis \[[@B21-ijms-21-05387]\] or whole-genome transcriptomic profiles \[[@B22-ijms-21-05387],[@B23-ijms-21-05387]\], to elucidate cancer mechanisms in more detail. However, little has been reported on an integrated strategy consisting of the methylation analysis and in vitro CTA. We previously reported a method that couples the in vitro Bhas 42 CTA with methyl-CpG-binding domain protein sequencing (MBD-Seq) to utilize the CTA within an integrated approach for testing and assessment (IATA) for NGTXCs \[[@B24-ijms-21-05387]\].

Herein, we analyzed the methylation profiles of transformed foci induced by seven NGTXCs using the RRBS method to distinguish the different modes of action of NGTXCs with the aim of predicting essential information regarding their carcinogenic mechanisms. Combining restriction enzymes and bisulfite sequencing, RRBS enriches genomic regions with a high CpG content \[[@B25-ijms-21-05387]\]. Furthermore, RRBS can be applied to quickly identify aberrant methylation in cancer because this technique is highly sensitive \[[@B26-ijms-21-05387]\]. As such, we provide information regarding the methylation signatures in foci during NGTXC-induced cell transformation and reveal, using ingenuity pathway analysis (IPA), that the genes with differentially methylated regions (DMRs) at CpG sites are linked to cancer-related categories in the enriched functional annotations. As far as we know, this study is among the first to elucidate a unique pathway associated with NGTXC-induced carcinogenesis based on a genome-wide methylation approach.

2. Results {#sec2-ijms-21-05387}
==========

2.1. Selection of Test Articles {#sec2dot1-ijms-21-05387}
-------------------------------

The selection of 10 NGTXCs was based on carcinogenicity and genotoxicity reviews by previously published reports \[[@B5-ijms-21-05387],[@B27-ijms-21-05387],[@B28-ijms-21-05387]\] ([Table 1](#ijms-21-05387-t001){ref-type="table"}). The selected 10 NGTXCs were also predicted to be negative through Derek/Sarah analysis, which is accepted by regulators under International Conference on Harmonisation (ICH) guideline M7 on the assessment and control of DNA-reactive impurities in pharmaceuticals \[[@B29-ijms-21-05387]\]. In particular, a structural alert for non-genotoxic carcinogenicity was noted in four NGTXCs (DEHP, TCDD, rosuvastatin, and sodium saccharin) by the OECD quantitative structure--activity relationship (QSAR) toolbox \[[@B30-ijms-21-05387],[@B31-ijms-21-05387]\]. [Table 2](#ijms-21-05387-t002){ref-type="table"} lists the diversity in the modes of action of 10 NGTXCs. The non-genotoxic modes of action include the dysregulation of the hepatic iron metabolism, choline deficiency, peroxisome proliferation, and calculus formation.

2.2. Transformation Assay {#sec2dot2-ijms-21-05387}
-------------------------

As a first step towards the development of an integrated approach, the in vitro Bhas 42 CTA suggested by the OECD Working Group \[[@B8-ijms-21-05387]\] was performed on 10 NGTXCs. Cell growth assays were conducted to identify the most suitable concentration of each test article for the Bhas 42 CTA (data not shown). Three independent assays were carried out to assess cytotoxicity. Five to seven concentrations of each NGTXC were established based on the results of the cell growth assay. The highest concentration for the cell growth assay was set to 10 mM or 2 mg/mL according to an OECD guidance document \[[@B8-ijms-21-05387]\]. In the case of insoluble substances, the concentration range for the growth assay was set to include one concentration with a visible precipitate due to the limit of solubility. However, in the transformation assay for melamine, rosuvastatin, and D-limonene, no foci were formed even in the concentration range where no cytotoxicity was observed in the cell growth assay (data not shown). Thus, for these three test substances, the CTA was performed at a re-adjusted concentration range, which is low enough to form foci. The promoter activity of 10 NGTXCs was examined, and the results are summarized in [Table 3](#ijms-21-05387-t003){ref-type="table"}. Among the 10 NGTXCs, three (D-limonene, melamine, and rosuvastatin) showed negative results in the promotion test. Sodium saccharin, methapyrilene, DEHP, diethanolamine (DEA), TCDD, and cholic acid induced a more than two-fold increase in foci formation, while okadaic acid led to a relatively weak increase.

2.3. Identification and Distribution of DMRs {#sec2dot3-ijms-21-05387}
--------------------------------------------

To detect the critical methylation events associated with NGTXCs, we compared the DNA methylomes from seven Bhas 42 CTA-positive NGTXCs via RRBS analysis, which is an effective and economical method for analyzing the DNA methylation of a single base \[[@B18-ijms-21-05387],[@B19-ijms-21-05387]\]. DMRs, defined as genomic regions exhibiting methylation differences with more than 20% changes between the samples (untransformed cells vs. transformed foci) at a CpG site and achieving a false discovery rate (FDR)-adjusted *p*-value \< 0.05, were used for all the subsequent analyses. The complete list of DMRs associated with each NGTXC is included in [Supplementary Tables S1--S7](#app1-ijms-21-05387){ref-type="app"}. The average number of DMRs identified in each NGTXC are 730--1574, with the exception of 3796 DMRs for DEHP and 288 DMRs for okadaic acid (OA). DMRs identified in OA were relatively low compared to other CTA-positive NGTXCs probably due to the low transforming activity of OA as shown in [Table 3](#ijms-21-05387-t003){ref-type="table"}. We calculated the coefficient of correlation to investigate whether there was any relation between the number of DMRs and in vitro cell transformation. The number of DMRs appeared to be positively related to the number of foci formed in CTA, but the coefficient of correlation was low with the value of 0.4782. The scatter diagram and coefficient of correlation are presented in [Supplementary Figure S1](#app1-ijms-21-05387){ref-type="app"}. Interestingly, of the 3796 DMRs in DEHP, 3081 DMRs (81%) were hypermethylated, while the remaining 715 (19%) were hypomethylated ([Figure 1](#ijms-21-05387-f001){ref-type="fig"}A). Conversely, in DEA-induced transformed foci, 730 significant DMRs were detected, of which 146 (20%) were hypermethylated and 583 (80%) were hypomethylated. The DMRs in the promoter region, which were defined as DMRs within 1500 bp upstream and 1500 bp downstream from the transcription start site (TSS), were then segregated on the basis of methylation status ([Figure 1](#ijms-21-05387-f001){ref-type="fig"}B). With the exception of DEHP, the DMRs in the promoter regions showed slightly more bias toward hypermethylation than DMRs throughout the whole genome. [Figure 1](#ijms-21-05387-f001){ref-type="fig"}C shows the heatmap of the DNA methylation level at DMRs specific for each NGTXC using hierarchical agglomerative clustering with complete linkage.

Then, the distributions of the DMRs from the RRBS data were compared in terms of the following seven genomic features: (i) promoters (DMR within 1500 bp upstream and 1500 bp downstream from TSS); (ii) exon; (iii) intron; (iv) 5′-UTR; (v) 3′-UTR; (vi) downstream (a 3-kb region downstream of transcription termination sites); and (vii) distal intergenic regions. The distribution patterns appeared to be relatively similar among the six NGTXCs, except for OA ([Figure 1](#ijms-21-05387-f001){ref-type="fig"}D). Almost 40% of the identified DMRs were associated with the gene body (exon + intron). DMRs located within the intergenic regions were almost 40%. We also discovered that, on average, 15% of the identified DMRs were located in promoter regions, which are crucial for gene expression regulation. However, in the case of OA, DMRs were observed in the promoter regions at a frequency of 26.4%.

2.4. Overlapping DMRs in Promoter Regions across NGTXCs {#sec2dot4-ijms-21-05387}
-------------------------------------------------------

We focused on the DMRs in promoter regions that could be directly associated with gene expression. The overlapping DMRs with a methylation difference \>20% and adjusted *p*-value \< 0.05 in the promoter region (1500 bp upstream and 1500 bp downstream from the putative TSS) were selected. Of these shared DMRs in NGTXCs, the DMRs exhibiting methylation changes in the same direction were selected as "overlapping" DMRs. A complete list of the overlapping DMRs in promoter regions between each NGTXC is available in [Supplemental Table S8](#app1-ijms-21-05387){ref-type="app"}. In particular, there were 59 overlapping DMRs in the promoter region between DEHP and CA. This accounts for 31% of the 188 DMRs found in CA. However, the mode of actions (MOAs) of DEHP and CA were peroxisome proliferators and xenobiotic metabolizing enzyme inhibitors, respectively, and there was no similarity between the non-genotoxic carcinogenic mechanisms. Only three DMRs were found between OA and SS. [Table 4](#ijms-21-05387-t004){ref-type="table"} lists the genes harboring the overlapping DMRs in four or more NGTXCs. The 13 genes associated with overlapping DMRs in four NGTXCs were identified, of which seven were hypermethylated and six hypomethylated. Although two genes (H2-D1 and Mir705) harboring overlapping DMRs were found to be significantly differentially methylated between the transformed foci and controls across the five NGTXCs, the roles of these genes in cancer have not yet been investigated.

2.5. Enriched Functional Annotation and Canonical Pathway {#sec2dot5-ijms-21-05387}
---------------------------------------------------------

The functions associated with genes harboring DMRs identified for each NGTXC were annotated ([Table 5](#ijms-21-05387-t005){ref-type="table"}). For enriched function annotation, we used a list of DMRs with more than 30% changes between the samples (controls vs. the transformed foci) at a CpG site and achieving an FDR-adjusted *p*-value \< 0.05. In six NGTXCs, except SA, the genes with DMRs at CpG sites were significantly enriched in cancer-related categories, including "cancer", "cell-to-cell signaling and interaction", and "cell death and survival", although these were not the most enriched categories. On the other hand, the genes harboring DMRs in SA were significantly related to connective tissue development and function (*p* = 1.93 × 10^−5^). Additionally, as shown in [Table 6](#ijms-21-05387-t006){ref-type="table"}, several canonical pathways revealed the significant enrichment of the activation pathway of the retinoid acid receptor (RAR) and retinoid X receptor (RXR) families (in six NGTXCs), gustation pathways (in six NGTXCs), as well as the salvage pathway of pyrimidine ribonucleotides (in five NGTXCs), although these pathways were not observed as top hits. Overall, the annotations represent the trends of the malignant cell transformation of cells with NGTXC treatment.

2.6. Network Identification {#sec2dot6-ijms-21-05387}
---------------------------

We identified networks with scores over 5 for each NGTXC. [Figure 2](#ijms-21-05387-f002){ref-type="fig"} depicts the top two highest-scoring IPA-generated networks. One network (control vs. DEHP) with a score of 32, including genes for ERK1/2, NFκB (complex), NOS1, NOTCH4, PITX2, and PTPN11, was associated with cell-to-cell signaling and interaction, gene expression, nervous system development, and function. The other network (control vs. OA) with a score of 28 included genes for Ccl2, IFNG, IRS1, RUNX2, TNF, and TP53, was associated with cancer, cell death and survival, and organismal development. Networks related to "cell death and survival", which were considered to be linked to carcinogenesis, were identified in the other six NGTXCs, except for CA. [Supplementary Table S9](#app1-ijms-21-05387){ref-type="app"} features detailed information, including the molecules, score, and focus molecules, for each network.

3. Discussion {#sec3-ijms-21-05387}
=============

Genotoxic carcinogens (GTXCs) can be detected with a battery of genotoxicity tests, such as the measurement of primary DNA damage. However, NGTXCs act through a large and diverse variety of different and specific mechanisms that do not involve direct interaction with DNA \[[@B1-ijms-21-05387]\]. Thus, in contrast to GTXCs, a panel of assays addressing particular biological endpoints will be needed for the detection of NGTXCs \[[@B27-ijms-21-05387]\]. There is cumulative evidence that the in vitro Bhas 42 CTA is suitable for detecting NGTXCs acting via non-genotoxic mechanisms (Validation Study Report \[[@B4-ijms-21-05387],[@B5-ijms-21-05387]\]). However, in vitro CTA approaches do not provide information on the non-genotoxic mechanisms of carcinogenicity. Recently, it has been suggested that the development of an IATA could be the mechanistic basis for the carcinogenicity of NGTXCs \[[@B27-ijms-21-05387]\]. IATA can include a combination of methods that includes in vitro testing, QSAR, and -omics technologies.

Here, in order to identify the epigenetic modifications associated with NGTXC-induced carcinogenesis, we provided an integrated strategy consisting of (QSAR), in vitro Bhas 42 CTA, and DNA methylomes employing RRBS analysis. DNA methylation is one of the most important epigenetic modifications because aberrant methylation patterns are associated with the development diseases like cancer \[[@B45-ijms-21-05387],[@B46-ijms-21-05387]\]. RRBS is an efficient and high-throughput technique for analyzing genome-wide methylation profiles at a single nucleotide level \[[@B25-ijms-21-05387]\]. In addition, RRBS has been used to study several human diseases, including cancer \[[@B47-ijms-21-05387]\], neurodegenerative diseases \[[@B48-ijms-21-05387]\], aging \[[@B49-ijms-21-05387]\], and immunological diseases \[[@B50-ijms-21-05387]\]. Ten test articles selected as NGTXCs in this study were also predicted to be negative through Derek/Sarah analysis. Among the 10 NGTXCs, seven had positive results in the promotion testing of the in vitro Bhas 42 CTA. The average number of DMRs identified in the CTA-positive NGTXCs was 730--1574, with the exception of 3796 DMRs for DEHP and 288 DMRs for OA. We also discovered that, on average, 15% of the identified DMRs were located in promoter regions, which are crucial for gene expression regulation. With the exception of DEHP, the DMRs in the promoter regions showed slightly more bias toward hypermethylation than DMRs across the whole genome. Moreover, the 13 genes associated with overlapping DMRs in four NGTXCs were identified, of which seven were hypermethylated and six hypomethylated. In particular, although two genes (H2-D1 and Mir705) harboring overlapping DMRs were found to be significantly differentially methylated between transformed foci and controls across the five NGTXCs, and the roles of these genes in cancer have not yet been investigated.

To identify the major genetic events and processes occurring during malignant cell transformation by NGTXCs, we examined enriched functional annotations. The IPA analysis showed that, in six NGTXCs, except SA, the genes with DMRs at CpG sites were highly enriched in cancer-related categories, including "cancer", "cell-to-cell signaling and interaction", and "cell death and survival", although these were not the most enriched categories. Overall, the annotations represent the trends of the malignant cell transformation of the cells with NGTXC treatment. Interestingly, the potential contribution of the synaptic transmission and development throughout cell transformation by NGTXCs is evident from the enrichment of genes with annotations related to "cell-to-cell signaling and interaction". Although immunological synapses have been described previously in the context of the immune escape of glioma \[[@B51-ijms-21-05387]\], their role in cell transformation has not been determined as of yet.

Several canonical pathways were established to have a significant enrichment of the activation pathway of the RAR and RXR families (in six NGTXCs), gustation pathways (in six NGTXCs), as well as the salvage pathway of pyrimidine ribonucleotides (in five NGTXCs), though these pathways were not observed as top hits. With this, the cell growth and differentiation of malignant cells by retinoids has been reported to be regulated by RARs and RXRs \[[@B52-ijms-21-05387]\]. In addition, our results are in line with previous reports indicating that gustation pathways and the salvage pathway of pyrimidine ribonucleotides were identified via IPA in cancer cells \[[@B53-ijms-21-05387],[@B54-ijms-21-05387]\]. IPA also determined the functional networks relevant to NGTXC-induced cell transformation. The most significant network was defined as "cell-to-cell signaling and interaction" (with a score of 32), where genes including ERK1/2, NFκB (complex), NOS1, NOTCH4, PITX2, and PTPN11 are clustered. The second top-ranked network was "cell death and survival" (with a score of 28).

Taken together, we posit that the genes with DMRs at CpG sites in the transformed foci are linked to malignant cell transformation that the cells undergo during NGTXC treatment. Thus, the framework in this study demonstrated the possibility of using a combination of several tools to take advantage of an integrated approach. However, the functional annotations and canonical pathways identified through our IPA analysis did not exhibit a robust correlation with the modes of action previously reported for each NGTXC. Therefore, further study will be required for the development of a more efficient integrated approach that includes a methylation profile analysis.

4. Materials and Methods {#sec4-ijms-21-05387}
========================

4.1. Materials {#sec4dot1-ijms-21-05387}
--------------

The 10 NGTXCs used for the Bhas 42 CTA in this study were as follows: methapyrilene hydrochloride (MH) (CAS \# 135-23-9), D-limonene (CAS \# 5989-27-5), bis(2-ethylhexyl) phthalate (DEHP) (CAS \# 117-81-7), 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS \# 1746-01-6), okadaic acid (OA) (CAS \# 78111-17-8), cholic acid (CA) (CAS \# 81-25-4), diethanolamine (DEA) (CAS \# 111-42-2), rosuvastatin (CAS \# 287714-41-4), melamine (CAS \# 108-78-1), and sodium saccharin (SA) (CAS \# 128-44-9). All were obtained from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco's modified Eagle's medium/F12 (DMEM/F12), minimum essential medium (MEM), and fetal bovine serum (FBS) were purchased from Thermo Fisher Scientific (Carlsbad, CA, USA). Crystal violet (CV) and Giemsa staining solution were purchased from Sigma-Aldrich. In addition, 12-O-tetradecanoylphorbol 13-acetate (TPA, CAS \# 16561-29-8) was included as a positive control for the promotion assay. Test articles were dissolved in sterile distilled water or DMSO. The final concentration of distilled water was 1% in the culture medium, and that of DMSO was 0.1%.

4.2. Cell Lines and Cell Culture {#sec4dot2-ijms-21-05387}
--------------------------------

Bhas 42 cells, which were established from the BALB/c 3T3 cells through transfection with the v-Ha-*ras* gene \[[@B55-ijms-21-05387]\], were obtained from the Japan Health Sciences Foundation Health Science Research Resources Bank (Osaka, Japan). As previously described \[[@B24-ijms-21-05387]\], the cells were grown in MEM supplemented with 10% FBS (M10F). Only 60--70% of the confluent cells were sub-cultured. The cells were cultured in a humidified incubator under 5% CO~2~ and 95% O~2~. Three days prior to treatment with test articles, Bhas 42 cells were maintained in DMEM/F12 supplemented with 5% FBS (DF5F).

4.3. Cell Growth Assay {#sec4dot3-ijms-21-05387}
----------------------

The cell growth assays were performed prior to the transformation assays to determine the appropriate treatment concentrations of the test articles, as well as concurrently with every transformation assay to estimate the effect of the test articles on cell growth and survival. The cells were seeded, treated with a test article, and cultured until day 7. Three wells were prepared for each treatment group. On day 7, the cells were fixed with 10% formalin and stained with a 0.1% CV solution in 5% ethanol. CV was extracted from the stained cells with a solution containing 0.02 mol/L hydrochloric acid in 50% ethanol. The optical density of the extract was measured at a wavelength between 540 and 570 nm.

4.4. In Vitro Bhas 42 CTA for the Promotion Test {#sec4dot4-ijms-21-05387}
------------------------------------------------

The in vitro transformation assays were conducted according to the procedures reported by Sakai et al. \[[@B7-ijms-21-05387]\] with slight modifications. The Bhas 42 cells were seeded into each well of 6-well microplates at 2 mL volumes (7000 cells/well, day 0). Six wells were prepared for each treatment group. The cells were cultured for four days without medium exchange. On day 4, day 7, and day 11, the culture medium was replaced with fresh medium containing a test article or vehicle alone, and the treatment in the promotion phase was continued until day 14. The media were not changed during the last 7 days of culture. The cells were then fixed with methanol and stained with Giemsa solution.

4.5. Isolation of Transformed Foci {#sec4dot5-ijms-21-05387}
----------------------------------

For the methylation profiling analysis, the foci that formed in the culture dish were cloned with cloning cylinders (6 mm internal diameter, 8 mm external diameter, 8 mm length). The foci were inspected, and the desired foci were circled. Growth medium was removed from the dish and cells washed with PBS. Then, a sterile cloning cylinder with one edge coated with silicone grease was placed around the selected focus, and 40 μL of trypsin was added to the cloning cylinder well. Cell lines were established from each focus, which were placed in 6-well plates containing M10F. After cellular growth for 10 to 15 days with frequent changes of medium, the genomic DNA from one established cell line was analyzed for methylation with RRBS.

4.6. Genomic DNA Extraction and Reduced-Representation Bisulfite Sequencing (RRBS) {#sec4dot6-ijms-21-05387}
----------------------------------------------------------------------------------

For the whole-genome DNA, RRBS was performed by C&K Genomics, Inc. (Seoul, Korea) Briefly, genomic DNA was quantified in a Victor2 spectrophotometer (PerkinElmer, Boston, MA, USA) using the Quant-iT™ PiboGreen™ RNA Assay Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. To construct the Msp1 and Apek1 digested RRBS library, 500 ng of genomic DNA was incubated at 37 °C for 24 h. The digested products were purified with a MinElute PCR Purification Kit (Qiagen, Valencia, SC, USA). After purification, the digested products were blunt-ended, and then the dA was added, followed by methylated-adapter ligation. A range of 160--420 adapter-ligated fractions was excised from a 2% agarose gel. Bisulfite conversion was conducted using a ZYMO EZ DNA Methylation-Gold Kit™ (ZYMO research, Irvine, CA, USA) following the manufacturer's instructions. The final libraries were generated by PCR amplification using PfuTurbo Cx Hotstart DNA Polymerase (Agilent Technologies, Santa Clara, CA, USA). RRBS libraries were evaluated by an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Libraries were quantified by qPCR using the CFX96 Real-Time System (Bio-Rad, Hercules, CA, USA). After normalization, the sequencing of the prepared library was conducted on the Nextseq system (Illumina, San Diego, CA, USA) with 75-bp paired-end reads.

4.7. RRBS Data Analysis {#sec4dot7-ijms-21-05387}
-----------------------

RRBS data were preprocessed by the following steps. Briefly, low-quality adapter sequences in the raw reads were trimmed using TrimGalore (version 0.6.5) with Cutadapt (version 1.18) \[[@B56-ijms-21-05387]\]. Quality checks of the clean data were conducted with FastQC (version 0.11.5), then high-quality reads were mapped to the reference genome (Mouse genome assembly GRCm38.p6) using Bismark (version 0.22.3) with bowtie2 (version 2.3.5) \[[@B57-ijms-21-05387]\]. Data quality was shown in [Supplementary Table S10](#app1-ijms-21-05387){ref-type="app"}. During the NGTXC-induced cell transformation, the DMRs were identified using DMRcaller (version 1.18.0), which uses the Bismark output data as input \[[@B58-ijms-21-05387]\]. We considered 100-bp tilling bins for computing the differentially methylated cytosines, and performed a score test between the methylated and total reads in a bin for the samples (untransformed cells vs. transformed foci). We selected the bins where the FDR-adjusted *p*-value was less than 0.05 and the difference in level of methylation was at least 20% in the CG context, containing at least four cytosines (with at least four reads per cytosine). The identified DMRs were annotated using ChipSeeker \[[@B59-ijms-21-05387]\] with gene annotation information from the R package TxDb.Mmusculus.UCSC.mm10.knownGene and org.Mm.eg.db \[[@B60-ijms-21-05387]\]. Promoters were defined as the DMRs within 1500 bp upstream and 1500 bp downstream from the TSS.

4.8. Molecular Network, Pathway, and Functional Analysis {#sec4dot8-ijms-21-05387}
--------------------------------------------------------

Enriched functional annotation, gene network identification, and canonical pathway analysis (generalized pathways that represent the common properties of a particular signaling module or pathway) were performed using Ingenuity Pathway Analysis software (Ingenuity Systems, Redwood City, USA). We utilized a list of DMRs with more than 30% changes between the samples (controls vs. transformed foci) at a CpG site and achieving an FDR-adjusted *p*-value \< 0.05. The networks were identified using the scores calculated for each network according to the fit of the network to the set of the focus genes of the ingenuity analysis. The significance of the biofunctions and canonical pathways were tested by *p*-value. In addition, the canonical pathways were ranked by the ratio (number of genes from the input DMR data that maps to the pathway divided by the total number of molecules that exist in the canonical pathway).

Supplementary materials can be found at <https://www.mdpi.com/1422-0067/21/15/5387/s1>. Table S1. List of DMRs associated with cholic acid (CA); Table S2. List of DMRs associated with bis(2-ethylhexyl) phthalate (DEHP); Table S3. List of DMRs associated with okadaic acid (OA); Table S4. List of DMRs associated with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD); Table S5. List of DMRs associated with diethanolamine (DEA); Table S6. List of DMRs associated with methapyrilene hydrochloride (MH); Table S7. List of DMRs associated with sodium saccharin (SS). Table S8; List of overlapping DMRs in a promoter region between each NGTXC. Table S9; Networks with a score with scores over 5 in each NGTXC. Table S10; Summary of the data quality of RRBS performance. Figure S1. Association between DMRs and cell transformation.
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![Identification and distribution of the differentially methylated regions (DMRs) specific to each non-genotoxic carcinogen (NGTXC) during the cell transformation. (**A**) Histogram of the distribution of the relative number of hypermethylated and hypomethylated DMRs per NGTXC. (**B**) Histogram of DMRs in the promoter region (−1500--1500). In (**A**,**B**), the DMRs that were unique to each NGTXC-induced transformed focus were separated by methylation status and classified as hypermethylated or hypomethylated with respect to the untransformed cells. (**C**) The heatmap of the DNA methylation level at DMRs specific to each NGTXC. Each column represents a different NGTXC, and each row represents a different DMR specific to each NGTXC. The red color represents hypermethylation, while the green color represents hypomethylation. (**D**) The distribution of DMRs in different genomic regions: 3′-UTR, 5′-UTR, exon, intron, intergenic, promoter, and downstream (≤300).](ijms-21-05387-g001){#ijms-21-05387-f001}

![Top two networks based on ingenuity pathway analysis (IPA) showing interactions between the controls and the case. (**A**) Cell-to-cell signaling and interaction (control vs. DEHP). (**B**) Cancer, cell death and survival (control vs. OA). The lines between the genes represent known interactions (solid lines represent direct interactions; dashed lines represent indirect interactions). Each gene is displayed using shapes that represent the functional class of the gene product as indicated in the legend. The intensity of the red and green colors indicates the degree of up- and downregulation, respectively. A total of 25 networks (*p*-scores \> 18) are provided in [Supplementary Table S9](#app1-ijms-21-05387){ref-type="app"}.](ijms-21-05387-g002){#ijms-21-05387-f002}
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###### 

Published genotoxicity and carcinogenicity results for the test articles.

  Test Articles                        Genotoxicity                                                                                             Carcinogenicity                      ICH M7 Prediction (Derek/Sarah)   OECD QSAR Toolbox Prediction
  ------------------------------------ -------------------------------------------------------------------------------------------------------- ------------------------------------ --------------------------------- ---------------------------------------------------
  Methapyrilene hydrochloride (MH)     Equivocal in Ames test, Negative in in vitro CA and SCE, in vivo CA, SCE and MN                          Potent hepatocarcinogen in rats      -/-                               No alert found
  D-limonene                           Negative in Ames test, in vivo comet, in vitro CA                                                        Male rat kidney tumors               -/-                               No alert found
  bis(2-ethylhexyl) phthalate (DEHP)   Negative in Ames test, in vivo MN, in vitro MN, MLA                                                      IARC Group 2B                        -/-                               Structural alert for nongenotoxic carcinogenicity
  TCDD                                 Negative in Ames test, in vitro MLA, CA, SCE, in vivo CA                                                 IARC Group 1                         -/-                               Structural alert for nongenotoxic carcinogenicity
  Okadaic acid (OA)                    Negative in Ames test, in vitro CHO/HGPRT, but mutagenic to CHL cells                                    Tumor promoter on mouse skin         -/-                               No alert found
  Cholic acid (CA)                     Equivocal in Ames test, non-significant mutagenic activity in a battery of in vitro genotoxicity tests   Colon cancer promoter                -/-                               No alert found
  Diethanolamine (DEA)                 Negative in Ames test, in vivo MN, in vitro CA                                                           IARC Group 2B                        -/-                               No alert found
  Rosuvastatin                         Negative in Ames test, in vivo MN, in vitro CA, MLA                                                      Positive response in mice and rats   -/-                               Structural alert for nongenotoxic carcinogenicity
  Melamine                             Negative in Ame test, in vivo MN, in vitro CA                                                            Bladder carcinoma                    -/-                               Structural alert for genotoxic carcinogenicity
  Sodium saccharin (SA)                Negative in Ames test, in vivo CA and comet, in vitro MLA                                                Rat and mouse bladder tumors         -/equivocal                       Structural alert for nongenotoxic carcinogenicity

Abbreviations: Ames, reverse bacterial mutation assay in *Salmonella typhimurium*; in vitro CA, in vitro chromosomal aberration assay; in vivo MN, micronucleus test; SCE, sister chromatid exchange; MLA, mouse lymphoma assay; CHO, Chinese hamster ovary; CHL, Chinese hamster lung; HGPRT, hypoxanthine guanine phosphoribosyltransferase; IARC, International Agency for Research on Cancer; -, negative response. References: D-limonene, melamine, diethanolamine. DEHP, rosuvastatin, sodium saccharin \[[@B28-ijms-21-05387]\]; ethapyrilene hydrochloride \[[@B32-ijms-21-05387]\]; TCDD \[[@B33-ijms-21-05387]\]; Okadaic acid \[[@B34-ijms-21-05387]\].
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###### 

Mode of actions of the test articles.

  Test Articles                        Mode of Actions                                                          Reference
  ------------------------------------ ------------------------------------------------------------------------ --------------------------
  Methapyrilene hydrochloride          The dysregulation of hepatic iron metabolism                             \[[@B35-ijms-21-05387]\]
  D-limonene                           α2 μ-globulin nephropathy                                                \[[@B36-ijms-21-05387]\]
  Bis(2-ethylhexyl) phthalate (DEHP)   Peroxisome proliferators                                                 \[[@B37-ijms-21-05387]\]
  TCDD                                 Receptor binding                                                         \[[@B38-ijms-21-05387]\]
  Okadaic acid                         Inhibitors of protein serine/threonine phosphatases                      \[[@B39-ijms-21-05387]\]
  Cholic acid                          Inhibition of xenobiotic metabolizing enzyme                             \[[@B40-ijms-21-05387]\]
  Diethanolamine                       Choline deficiency                                                       \[[@B41-ijms-21-05387]\]
  Rosuvastatin                         Inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase   \[[@B42-ijms-21-05387]\]
  Melamine                             Calculus formation                                                       \[[@B43-ijms-21-05387]\]
  Sodium saccharin                     Calculus formation                                                       \[[@B44-ijms-21-05387]\]
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###### 

Bhas 42 cell transformation assay (Promotion test).

  Conc.                                    \% Viability                                Foci/Well               Conc.       \% Viability   Foci/Well
  ---------------------------------------- ------------------------------------------- ----------------------- ----------- -------------- ------------------
  Sodium saccharin (128-44-9)---Positive   Methapyrilene HCl (135-23-9)---Positive                                                        
  0 (μg/mL)                                100                                         3.5 ± 1.38 ^(a)^        0 (μg/mL)   100            7.2 ± 0.75
  500                                      107                                         9.3 ± 1.97 \*\*^,(b)^   3           107            14.5 ± 2.59 \*\*
  750                                      113                                         8.8 ± 1.94 \*\*         3.5         110            16.0 ± 1.26 \*\*
  1000                                     93                                          9.3 ± 1.03 \*\*         4           101            13.8 ± 1.60 \*\*
  1250                                     106                                         9.7 ± 1.21 \*\*         4.5         100            15.0 ± 2.00 \*\*
  1500                                     94                                          8.2 ± 1.94 \*\*         5           96             14.5 ± 2.43 \*\*
  1750                                     101                                         7.3 ± 2.16 \*\*         5.5         99             10.5 ± 3.27
  DEHP (117-81-7)---Positive               D-limonene (5989-27-5)---Negative                                                              
  0 (μg/mL)                                100                                         11.0 ± 1.79             0 (μg/mL)   100            12.7 ± 3.01
  2.5                                      93                                          13.8 ± 2.48             12.5        103            14.7 ± 3.72
  5                                        92                                          19.5 ± 2.17 \*\*        15          103            12.2 ± 3.19
  10                                       91                                          20.5 ± 4.76 \*\*        17.5        102            14.0 ± 2.00
  25                                       95                                          18.5 ± 3.73 \*\*        20          101            12.8 ± 3.60
  50                                       93                                          18.5 ± 1.64 \*\*        22.5        83             12.3 ± 2.07
  100                                      90                                          13.0 ± 3.52             25          78             9.8 ± 2.14
  Melamine (108-78-1)---Negative           Rosuvastatin (287714-41-4)---Negative                                                          
  0 (μM)                                   100                                         7.5 ± 1.76              0 (μg/mL)   100            8.0 ± 0.89
  0.25                                     92                                          7.8 ± 2.23              0.1         103            8.8 ± 1.83
  0.5                                      96                                          8.2 ± 2.48              0.25        100            7.8 ± 1.83
  1                                        95                                          9.0 ± 2.68              0.5         102            8.7 ± 1.51
  2.5                                      98                                          9.7 ± 3.08              0.75        117            8.2 ± 1.94
  5                                        96                                          10.8 ± 2.23             1           125            9.8 ± 3.13
  10                                       103                                         9.3 ± 3.20              2           116            8.7 ± 1.63
  Diethanolamine (111-42-2)---Positive     Okadaic acid (78111-17-8)---Weak positive                                                      
  0 (μg/mL)                                100                                         7.8 ± 1.94              0 (ng/mL)   100            8.8 ± 1.17
  10                                       99                                          14.0 ± 3.22 \*          0.25        100            11.7 ± 2.25
  25                                       117                                         16.7 ± 2.66 \*\*        0.5         109            13.0 ± 3.35 \*
  50                                       114                                         12.8 ± 3.87             0.75        97             11.2 ± 3.49
  75                                       110                                         17.5 ± 2.07 \*\*        1           102            12.8 ± 2.14 \*
  100                                      88                                          16.8 ± 3.66 \*\*        2           118            6.2 ± 0.75
  150                                      112                                         17.8 ± 4.71 \*\*        3           117            5.0 ± 1.41
  TCDD (1746-01-6)---Positive              Cholic acid (81-25-4)---Positive                                                               
  0 (nM)                                   100                                         11.3 ± 1.37             0 (μg/mL)   100            5.0 ± 2.28
  10                                       77                                          20.0 ± 3.35 \*\*        10          124            8.8 ± 2.48
  25                                       86                                          19.3 ± 3.14 \*\*        25          119            9.0 ± 1.79 \*
  50                                       81                                          21.2 ± 0.75 \*\*        50          107            9.3 ± 1.97 \*
  75                                       85                                          18.8 ± 3.43 \*\*        100         122            9.0 ± 3.22 \*
  100                                      89                                          19.7 ± 2.25 \*\*        250         103            10.0 ± 2.68 \*\*
  200                                      79                                          17.3 ± 1.86 \*\*        500         131            11.8 ± 2.99 \*\*

^(a)^ Values represent the mean SD of six wells per group. ^(b)^ \*\* *p* \< 0.01 and \* *p* \< 0.05 as compared with vehicle control, as determined by Dunnett's *t* test.
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###### 

Genes harboring the overlapping DMRs.

  Associated Gene                                                               Description                                   DMR Position                      DMR Distance from TSS ^(1)^   DMCs Number   Methylation       NGTXC
  ----------------------------------------------------------------------------- --------------------------------------------- --------------------------------- ----------------------------- ------------- ----------------- -------------------
  **Genes harboring overlapping DMRs in 4 NGTXCs, -induced transformed foci**                                                                                                                                                 
  Asic1                                                                         Acid-sensing (proton-gated) ion channel 1     chr15: 99,691,202--99,691,300     −933                          8             hypomethylated    DEHP/OA/TCDD/MH
  Gm14169                                                                       Predicted gene 14169                          chr2: 156,613,303--156,613,401    21                            18            hypermethylated   CA/DEHP/OA/TCDD
  Gm7337                                                                        DAZ interacting protein 1 pseudogene          chr5: 87,851,102--87,851,200      584                           10            hypomethylated    CA/DEHP/OA/MH
  Gpsm2                                                                         G-protein signaling modulator 2               chr3: 108,721,702--108,721,900    216                           26            hypomethylated    CA/DEHP/OA/TCDD
  Irs1                                                                          Insulin receptor substrate 1                  chr1: 82,290,404--82,290,502      914                           18            hypermethylated   OA/TCDD/DEA/SS
  Mpv17                                                                         MpV17 mitochondrial inner membrane protein    ch5: 31,154,402--31,154,500       −151                          8             hypermethylated   CA/DEHP/OA/TCDD
  Nexn                                                                          Nexilin                                       chr3: 152,265,802--152,265,900    −7                            22            hypomethylated    DEHP/DEA/MH/SS
  Nrip2                                                                         Nuclear receptor interacting protein 2        chr6: 128,401,302--128,401,400    1009                          2             hypomethylated    CA/DEHP/TCDD/SS
  Nsun7                                                                         NOL1/NOP2/Sun domain family, member 7         chr5: 66,261,102--66,261,200      790                           10            hypomethylated    CA/TCDD/DEA/SS
  Pcdh7                                                                         Protocadherin 7                               chr5: 57,720,202--57,720,300      79                            14            hypermethylated   CA/OA/DEA/MH
  Pou6f1                                                                        POU domain, class 6, transcription factor 1   chr15: 100,599,102--100,599,200   664                           6             hypermethylated   CA/DEHP/TCDD/SS
  Unc13a                                                                        Unc-13 homolog A                              chr8: 71,668,402--71,668,500      −320                          12            hypermethylated   CA/DEHP/OA/TCDD
  Zfp882                                                                        Zinc finger protein 882                       chr8: 71,908,855--71,908,954      0                             14            hypermethylated   TCDD/DEA/MH/SS
  **Genes harboring overlapping DMRs in 5 NGTXCs-induced transformed foci**                                                                                                                                                   
  H2-D1                                                                         Histocompatibility 2, D region locus 1        chr17: 35,263,302--35,263,400     206                           23            hypomethylated    CA/DEHP/DEA/MH/SS
  Mir705                                                                        MicroRNA 705                                  chr6: 85,337,102--85,337,200      −729                          6             hypomethylated    DEHP/OA/DEA/MH/SS

^(1)^ TSS, transcription start site (1500 bp downstream and 1500 bp upstream from TSS)---\> Promoter. Abbreviation: DMCs, differentially methylated cytosines
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###### 

Top 3 and significant enriched functional annotations of the differentially methylated regions between the control and the NGTXC-treated group (*p*-value \< 0.05 and proportion of methylation difference \>0.3).

  NGTXC                                                   Categories                                   Disease or Functions Annotation        *p*-Value       Number of Molecules
  ------------------------------------------------------- -------------------------------------------- -------------------------------------- --------------- ---------------------
  Cholic acid                                             Cellular assembly and organization           Release of vesicles                    0.00605         2
  Lipid metabolism                                        Concentration of malonyl-coenzyme A          0.00913                                1               
  Embryonic development                                   Attachment of chorioallantoic membrane       0.00913                                1               
  Cancer, cellular growth and proliferation               Proliferation of mammary tumor cells         0.0182                                 1               
  DEHP                                                    Behavior                                     Learning                               7.93 × 10^−6^   25
  Cell-to-cell signaling and interaction                  Uptake of neurotransmitter                   1.85 × 10^−5^                          5               
  Neurological Disease                                    Cognitive impairment                         0.00009                                16              
  Cell death and survival                                 Apoptosis of tumor cell lines                0.0053                                 13              
  Okadaic aicd                                            Gastrointestinal disease                     Meteorism                              0.000468        2
  Cell-to-cell signaling and interaction                  Developmental process of synapse             0.000555                               4               
  Respiratory disease                                     Abnormal secretion of pulmonary surfactant   0.00135                                2               
  TCDD                                                    Cellular movement                            Cellular infiltration by macrophages   7.68 × 10^−6^   9
  Behavior                                                Long-term recognition memory                 5.16 × 10^−5^                          4               
  Cardiovascular system development and function          Systolic pressure                            0.00014                                7               
  cancer                                                  Cell transformation                          0.00125                                9               
  Cell death and survival                                 Apoptosis                                    0.00531                                17              
  Diethanol-amine                                         Embryonic development                        Formation of visceral endoderm         0.000195        2
  Cell cycle                                              Aneuploidy of embryonic cell lines           0.000291                               2               
  Cell cycle                                              Aneuploidy of fibroblast cell lines          0.000407                               2               
  Cell-to-cell signaling and interaction                  Developmental process of synapse             0.00116                                4               
  Cancer                                                  Hyperplasia of urothelium                    0.00446                                1               
  Methapyrilene HCl                                       Connective tissue development and function   Osteogenesis                           0.00316         2
  Cell-to-cell signaling and interaction                  Synaptic transmission                        0.00793                                6               
  Reproductive system development and function            Gestation                                    0.00814                                3               
  Sodium saccharin                                        Connective tissue development and function   Thickness of bone                      1.93 × 10^−5^   7
  Skeletal and muscular system development and function   Mineralization of bone                       3.44 × 10^−5^                          8               
  Connective tissue disorders                             Synostosis of cranium                        6.38 × 10^−5^                          2               
  Behavior                                                Social behavior                              9.72 × 10^−5^                          6               
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###### 

Top 3 and the significant canonical pathways of the differentially methylated regions between the control and the NGTXC-treated group (*p*-value \< 0.05 and proportion of methylation difference \>0.3).

  NGTXC                                            Ingenuity Canonical Pathways                                   −log (*p*-value)   Ratio                                                                            Molecules
  ------------------------------------------------ -------------------------------------------------------------- ------------------ -------------------------------------------------------------------------------- -------------------------------------------------------------------------------------
  Cholic acid                                      Notch signaling                                                2.37               0.0833                                                                           CNTN1, DTX1, LFNG
  Axonal guidance signaling                        1.97                                                           0.0214             ADAM19, ADAMTS1, GNG2, MYL12A, PRKAR1B, SEMA4A, SEMA4G, SEMA6C, SRGAP1, SRGAP3   
  Thyroid hormone biosynthesis                     1.57                                                           0.333              IYD                                                                              
  RAR activation                                   1.02                                                           0.0211             Akr1b10, NRIP2, PRKAR1B, SMARCD3                                                 
  Gustation pathway                                0.863                                                          0.0214             GNG2, PDE1B, PRKAR1B                                                             
  Salvage pathways of pyrimidine ribonucleotides   0.695                                                          0.022              DAPK1, GRK4                                                                      
  DEHP                                             Dopamine-DARPP32 feedback in cAMP Signaling                    3.54               0.0692                                                                           GNAI1, GRIN1, GRIN3B, KCNJ12, NOS1, PPP1R1B, PPP2R5A, PRKACA, PRKAR1B, PRKCZ, PRKG2
  Notch signaling                                  2.3                                                            0.111              DLL4, DTX1, HEY1, NOTCH4                                                         
  nNOS signaling in neurons                        1.95                                                           0.0889             GRIN1, GRIN3B, NOS1, PRKCZ                                                       
  Gustation pathway                                1.25                                                           0.0429             ASIC1, GNG2, P2RY12, PDE6B, PRKACA, PRKAR1B                                      
  Salvage pathways of pyrimidine ribonucleotides   0.585                                                          0.033              AK1, DAPK1, GRK4                                                                 
  Okadaic aicd                                     Glutamate degradation II                                       1.96               0.333                                                                            GOT2
  L-Serine degradation                             1.96                                                           0.333              SDS                                                                              
  Aspartate biosynthesis                           1.96                                                           0.333              GOT2                                                                             
  RAR activation                                   1.49                                                           0.0158             Akr1b10, MAP2K5, NSD1                                                            
  Salvage pathways of pyrimidine ribonucleotides   1.36                                                           0.022              DAPK1, GRK4                                                                      
  Gustation pathway                                1.03                                                           0.0143             ASIC1, CACNB1                                                                    
  TCDD                                             Pyridoxal 5′-phosphate salvage pathway                         2.48               0.0625                                                                           GRK4, MAP2K6, PDXK, PKN1
  PPARα/RXRα activation                            2.1                                                            0.0331             APOA1, GOT2, IRS1, MAP2K6, PPARA, PRKAR1A                                        
  Apelin liver signaling pathway                   1.6                                                            0.0769             APLNR, IRS1                                                                      
  Salvage pathways of pyrimidine ribonucleotides   1.25                                                           0.033              GRK4, MAP2K6, PKN1                                                               
  Gustation pathway                                0.824                                                          0.0214             ASIC1, CACNA1D, PRKAR1A                                                          
  Diethanolamine                                   Regulation of the epithelial--mesenchymal Transition pathway   1.99               0.0211                                                                           CLDN3, FGF19, FGFR2, NOTCH1
  Glutamate degradation II                         1.88                                                           0.333              GOT2                                                                             
  Aspartate Biosynthesis                           1.88                                                           0.333              GOT2                                                                             
  Cancer drug resistance by drug efflux            1.56                                                           0.0345             miR-133, PTEN                                                                    
  Gustation pathway                                0.889                                                          0.0143             CACNB1, PDE8B                                                                    
  PPARα/RXRα activation                            0.714                                                          0.011              GOT2, IRS1                                                                       
  Methapyrilene HCl                                γ-glutamyl cycle                                               4.14               0.3                                                                              GGCT, GGT6, GGT7
  Leukotriene biosynthesis                         2.34                                                           0.167              GGT6, GGT7                                                                       
  Valine degradation I                             1.99                                                           0.111              ABAT, SDS                                                                        
  Autophagy                                        1.05                                                           0.0345             CTSF, ULK1                                                                       
  Phagosome maturation                             0.921                                                          0.0214             CTSF, HLA-A, TCIRG1                                                              
  VDR/RXR activation                               0.839                                                          0.0256             BGLAP, IGFBP5                                                                    
  Salvage pathways of pyrimidine Ribonucleotides   0.264                                                          0.011              CDK5                                                                             
  Sodium saccharin                                 Gustation pathway                                              3.03               0.0429                                                                           P2RX7, P2RY12, PDE1B, PDE8B, PDE9A, PRKACA
  tRNA splicing                                    2.37                                                           0.0732             PDE1B, PDE8B, PDE9A                                                              
  G-protein coupled receptor signaling             1.68                                                           0.0225             P2RY12, PDE1B, PDE8B, PDE9A, PRKACA, PRKCB                                       
  VDR/RXR activation                               1.61                                                           0.0385             PRKCB, RUNX2, SPP1                                                               
  Phagosome maturation                             1.58                                                           0.0286             ATP6V1G3, HLA-A, LPO, TCIRG1                                                     
